The COVID-19 Delta variant poses an extreme threat to every person in the world.
But, the latest data obtained from a trial in South Africa showed that the Johnson & Johnson coronavirus vaccine is effective against the B.1.617.2 variant that originated in India in December 2020.
The clinical trial has involved nearly 480,000 South African workers.
J&J Vaccine Shows Promising Results in South Africa
A healthcare worker fills a syringe from a vial with a dose of the Johnson & Johnson vaccine against the COVID-19 coronavirus as South Africa proceeds with its inoculation campaign at the Klerksdorp Hospital on February 18, 2021.
According to a report by The Wall Street Journal on Friday, Aug. 6, the single-dose vaccine has posted an impressive rating against the highly contagious Delta variant.
Last month, almost 480,000 healthcare workers joined a clinical trial in South Africa. The study in the country, which is called "Sisonke," has concluded that Johnson & Johnson was "highly effective" against the Delta strain with a 71% efficacy rate.
Against death, the J&J vaccine was proven to be 96% effective. The clinical test has persisted for eight months.
"These results show there is no need for a booster yet," South African Medical Research Council president Glenda Gray said.
J&J's Case of Blood Clots
Like the other COVID-19 vaccines, the Johnson & Johnson vaccine has shown some side effects that led to its temporary suspension in South Africa.
In April, the experts found out that the first single-shot vaccine can result in some rare cases of blood clots among the patients.
In the United States, the authorities decided to stop the distribution of the J&J vaccine after discovering that six people reported blood clotting after receiving the dose.
At that time, the CDC's advisory committee said that they have no sufficient information about the people who could potentially experience the side effects.
According to the study of the researchers from the J&J company, there was no need anymore for an additional dose since their vaccines were already proven to neutralize the dangerous COVID-19 variants.
As per CDC's claim in June, the Johnson & Johnson COVID-19 vaccine has less protection against the Delta variant.
Meanwhile, the Food and Drug Administration in the US has issued that some patients suffered from the Guillain-Barre syndrome upon taking a shot.
Based on the previous findings of the experts, the Janssen vaccine has been the least efficient vaccine against the Delta strain when compared to Moderna and Pfizer vaccines.
Read Also: COVID-19 Symptoms Can Be Lessened By As Much as 70% Using Drug Meant for Treating Cholesterol
J&J Supplies in Africa
From another report by Bloomberg, Africa has been conducting rollouts for the Janssen vaccine until 2022. The continent agreed to the 400-million supply of vaccines across the regions.
In a study dated Feb. 17 to May 17, the vaccine was distributed to the health workers living in 120 rural and urban places. The experts said that the upcoming batch of data about this vaccine will come soon.
According to Gray, they have noted two cases of thrombocytopenia thrombosis syndrome, a rare blood clotting incident in the patients. Fortunately, both of them managed to recover.
Related Article: Johnson & Johnson's COVID-19 Vaccine is Protective Against Delta Variants, But Is It Safe for Public Use?
This article is owned by Tech Times
Written by Joseph Henry
